(Q37804830)

23 August 2017

title

Optimizing therapeutic antibody function: progress with Fc domain engineering (English)

1 reference

23 August 2017

1 reference

Etsuji Kaneko

1

1 reference

23 August 2017

Rinpei Niwa

series ordinal

2

1 reference

23 August 2017

publication date

1 February 2011

1 reference

23 August 2017

1 reference

23 August 2017

volume

25

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

1-11

1 reference

https://scigraph.springernature.com/pub.10.2165/11537830-000000000-00000

23 August 2017

exact match

0 references

cites work

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Replacing the complementarity-determining regions in a human antibody with those from a mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Making antibodies by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineering therapeutic antibodies for improved function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Crystal structure of the complex of rat neonatal Fc receptor with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Allelic polymorphisms of human Fc gamma receptor IIA and Fc gamma receptor IIIB. Independent mechanisms for differences in human phagocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Enhanced antibody half-life improves in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The alpha1-6-fucosyltransferase gene and its biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Humanization of yeast to produce complex terminally sialylated glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Recombinant human hexamer-dominant IgM monoclonal antibody to ganglioside GM3 for treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

FcgammaRIV: a novel FcR with distinct IgG subclass specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Optimization of Fc-mediated effector functions of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

In vitro characterization of five humanized OKT3 effector function variant antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

IgG2m4, an engineered antibody isotype with reduced Fc function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

An efficient route to human bispecific IgG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Delivery of antigen to CD40 induces protective immune responses against tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

21 January 2018

Troybodies and pepbodies

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

Immunogenicity screening in protein drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11537830-000000000-00000

10.2165/11537830-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

23 August 2017

1036760841

0 references

1 reference